Management & Regulatory

How Will Bora’s Stake in Tanvex Shape the Biotech Industry’s Future?
Management & Regulatory How Will Bora’s Stake in Tanvex Shape the Biotech Industry’s Future?

The acquisition of a 30.5% stake in Tanvex Biopharma by Bora Pharmaceuticals is a pivotal development in the biotech sector. As the largest single corporate shareholder in Tanvex, Bora aims to leverage this strategic partnership to enhance its competitive edge in the global biopharmaceutical

How Will Overturning Chevron Doctrine Affect Biopharma Industry?
Management & Regulatory How Will Overturning Chevron Doctrine Affect Biopharma Industry?

The recent decision by the Supreme Court to overturn the Chevron doctrine marks a significant shift in administrative law, with profound implications for the healthcare industry, particularly for federal regulators like the FDA (Food and Drug Administration) and the CMS (Centers for Medicare

Navigating Early-Stage Biotech: Rise of the Build-to-Buy Strategy
Management & Regulatory Navigating Early-Stage Biotech: Rise of the Build-to-Buy Strategy

The early-stage biotech investment landscape has undergone substantial changes in recent years. From the buoyant investment period during the pandemic to the current stabilization at pre-pandemic levels, the sector faces a mix of challenges and evolving strategies. One of the most significant

Avantor Celebrated for Biopharma Innovation at KBEA 2024 Awards
Management & Regulatory Avantor Celebrated for Biopharma Innovation at KBEA 2024 Awards

The Korea Biopharma Excellence Awards (KBEA) 2024 marked a significant moment for Avantor, a leader in providing mission-critical products and services across life sciences and advanced technologies. Avantor’s recognition at these awards underscores their unwavering commitment to innovation and e

Can Biotech IPOs Succeed Amid Financial Challenges and Market Gloom?
Management & Regulatory Can Biotech IPOs Succeed Amid Financial Challenges and Market Gloom?

In recent years, the biotech sector has faced significant challenges in the initial public offering (IPO) market. The economic downturn and financial uncertainties have created a tough environment for companies looking to go public. However, some biotech firms, such as Bicara Therapeutics and Zenas

Pharma Faces Hurdles in Sustainability Despite Business Gains
Management & Regulatory Pharma Faces Hurdles in Sustainability Despite Business Gains

In an era where sustainability is no longer an option but a necessity, the pharmaceutical industry finds itself grappling with significant challenges in its commitment to sustainable practices. A recent survey by Cytiva and FT Longitude paints a complex picture of the industry’s sustainability e

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later